Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis
NCT04176328Phase 1Completed
- Sponsor
- NeuPharma
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teicoplanin in cystic fibrosis (CF) and Staphylococcus aureus infection, sponsored by NeuPharma. Primary endpoint: Concentration of Teicoplanin in the sputum at 48 hours. Started Oct 2019; status: completed.
02
Drugs
teicoplanin
03
Conditions
cystic fibrosis (CF)Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT04176328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176328.